CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PrazosinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug543 New QIAstat-Dx fully automatic multiple PCR detection platform Wiki 1.00
drug775 Standard of care Wiki 0.35

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection

The purpose of this study is to assess the efficacy and safety of prazosin to prevent cytokine storm syndrome and severe complications in hospitalized patients with Coronavirus disease 2019 (COVID-19).

NCT04365257 COVID-19 Drug: Prazosin Other: Standard of care

Primary Outcomes

Description: Number of participants in each arm who expire.

Measure: Death

Time: up to day 60

Description: Number of participants in each arm who are hospitalized and requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO.

Measure: Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO

Time: up to day 60

Description: Number of participants in each arm who are hospitalized and requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2).

Measure: Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)

Time: up to day 60

Description: Number of participants in each arm who develop grade 3 and 4 adverse events during the study period.

Measure: Cumulative incidence of grade 3 and 4 adverse events

Time: up to day 60

Description: Number of participants in each arm who develop serious adverse events during the study period.

Measure: Number of participants with serious adverse events

Time: up to day 60

Description: Number of participants in each arm who develop symptomatic hypotension (systolic blood pressure <90 mmHg) or hypotension requiring cessation of prazosin.

Measure: Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin

Time: up to day 60

Secondary Outcomes

Description: Number of participants with laboratory abnormalities in peripheral blood (Lymphopenia, leukocytosis, anemia, thrombocytopenia, creatinine, AST/ALT, troponin I, pro-BNP, D-dimer, ferritin, interleukin (IL-6), soluble IL-2 receptor.

Measure: Number of participants with laboratory abnormalities in peripheral blood

Time: up to day 60

Description: Number of days with laboratory abnormalities in peripheral blood (Lymphopenia, leukocytosis, anemia, thrombocytopenia, creatinine, AST/ALT, troponin I, pro-BNP, D-dimer, ferritin, interleukin (IL-6), soluble IL-2 receptor.

Measure: Duration of laboratory abnormalities in peripheral blood

Time: up to day 60

Description: Number of participants with laboratory abnormalities in fractionated plasma catecholamines and plasma metanephrines.

Measure: Number of participants with laboratory abnormalities in plasma

Time: up to day 60

Description: Number of days with laboratory abnormalities in fractionated plasma catecholamines and plasma metanephrines.

Measure: Duration of laboratory abnormalities in plasma

Time: up to day 60

No related HPO nodes (Using clinical trials)